Shopping Cart
Remove All
Your shopping cart is currently empty
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | In Stock | In Stock | |
| 5 mg | $170 | In Stock | In Stock | |
| 10 mg | $263 | In Stock | In Stock | |
| 25 mg | $413 | In Stock | In Stock | |
| 50 mg | $579 | In Stock | In Stock | |
| 100 mg | $793 | In Stock | In Stock | |
| 200 mg | $1,090 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $240 | In Stock | In Stock |
| Description | ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy. |
| Targets&IC50 | Eph family tyrosine kinase:11 nM |
| In vitro | ALW-II-41-27 inhibits Ba/F3 cells (EC50<500 nM) transformed with Tel fusions of Kit, EphA3, Fms, KDR, FLT1, FGR, Src, Bmx, Lyn, and Bcr-Abl, and shows cross-reactivity with Bcr-Abl. Additionally, ALW-II-41-27 inhibits b-Raf, CSF1R, DDR1, DDR2, EphA2, EphA8, EphB1, EphB2, Kit, EphB3, Frk, Lck, EphA5, p38α, p38β, PDGFRβ, PDGFRα, and Raf1. |
| Synonyms | Eph receptor tyrosine kinase inhibitor |
| Molecular Weight | 607.69 |
| Formula | C32H32F3N5O2S |
| Cas No. | 1186206-79-0 |
| Smiles | CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(c4)-c4cccs4)c3)cc2C(F)(F)F)CC1 |
| Relative Density. | 1.321 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (90.51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.29 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.